Abstract: A device for removing unwanted objects from cut tobacco in a cut tobacco production line is disclosed, which includes: a raw cut tobacco feeding and conveying unit (N1), a heavy unwanted object removal unit (N2), a cut tobacco dispersion and recovery unit (N3), a moderate unwanted object removal unit (N4), a cut tobacco humidification unit (N5) and a light unwanted object removal unit (N6). An unwanted object removal method using the cut tobacco unwanted object removal device is also disclosed. The device and method of the disclosure can effectively remove unwanted objects from cut tobacco.

Abstract: A water environment temperature measurement tool includes measurement boxes and a counterweight box; a plurality of groups of the measurement boxes are provided; the counterweight box is movably connected with a group of measurement boxes; and each measurement box is provided with a temperature measurement instrument inside. The water environment temperature measurement tool further comprises: control mechanisms, each comprising a water inlet pipe, a water retaining member, an elastic member, a control assembly, a rotating seat, a rotating shaft, a second screw rod, a control seat and a rotary assembly. In the water environment temperature measurement tool of the present invention, the control mechanisms can achieve extraction and temperature measurement of water at different water body depths by cooperating with the measurement boxes and the temperature measurement instruments.

Abstract: A press hardening steel by a thin slab casting and direct rolling has a tensile strength of 1500 MPa or more. The press hardening steel has a components by weight percent: C: 0.21-0.25%, Si: 0.26-0.30%, Mn: 1.0-1.3%, P?0.01%, S?0.005%, Als: 0.015-0.060%, Cr: 0.25-0.30%, Ti: 0.026-0.030% or Nb: 0.026-0.030% or V: 0.026-0.030%, or a mixture of two or more of the above in any proportion; B: 0.003-0.004%, and N?0.005%. A method for producing the press hardening steel includes following steps: hot metal desulphurization; electric-furnace or converter smelting and refining; continuous casting; descaling, then entering a soaking furnace; heating and soaking; high-pressure water descaling, then entering a rolling mill; hot rolling; cooling; coiling; austenitizing; die deforming and quenching.

Abstract: The disclosure relates to a compound, having a structure of Formula I or a pharmaceutically acceptable salt thereof, herein, R1 is selected from hydrogen, fluorine, and chlorine; R2 and R3 are independently selected from hydrogen, alkyl, a substituted alkyl, alkenyl or a substituted alkenyl, alkynyl or a substituted alkynyl, and aryl, or R2 and R3 are connected to form a ring selected from a cycloalkyl, a substituted cycloalkyl, an aromatic heterocycle or a non-aromatic heterocycle; R4 is selected from hydrogen, cyano, alkyl, a substituted alkyl, alkenyl or a substituted alkenyl, alkynyl or a substituted alkynyl, and aryl; and R5 is selected from hydrogen, halogen, and haloalkyl. The disclosure further relates to a pharmaceutical composition containing the compound. The compound and the composition of the disclosure show significant activity in an aspect of treating AR-prostate cancer and triple-negative breast cancer.

Abstract: A press hardening steel by a thin slab casting and direct rolling has a tensile strength of 1500 MPa or more. The press hardening steel has a components by weight percent: C: 0.21-0.25%, Si: 0.26-0.30%, Mn: 1.0-1.3%, P?0.01%, S?0.005%, Als: 0.015-0.060%, Cr: 0.25-0.30%, Ti: 0.026-0.030% or Nb: 0.026-0.030% or V: 0.026-0.030%, or a mixture of two or more of the above in any proportion; B: 0.003-0.004%, and N?0.005%. A method for producing the press hardening steel includes following steps: hot metal desulphurization; electric-furnace or converter smelting and refining; continuous casting; descaling, then entering a soaking furnace; heating and soaking; high-pressure water descaling, then entering a rolling mill; hot rolling; cooling; coiling; austenitizing; die deforming and quenching.

Abstract: The present invention relates to use of a camptothecin derivative for preparing a medicament for the treatment of multiple myeloma. The medicament is represented by Formula I and can be pharmaceutically acceptable salts thereof. This medicament shows advantages in treatment of multiple myeloma and avoids drug resistance problems for existing drugs.

Abstract: The present invention relates to a water soluble derivative of camptothecin and preparation method thereof, the derivative having a structure of formula I and being appropriate in water solubility, and having anti-cancer activity and stability of lactonic ring. The present invention also relates to a method for synthesizing the compound and medical use of the compound.

Abstract: The present invention relates to a camptothecin derivative having a structure as represented by Formula (II), in which Xn+ is selected from H+, K+, Na+, Li+, Mg2+, Ca2+, Zn2+, Fe3+, and ammonium ion, while R1, R2, R3, and R4 independently represent a hydrogen, a hydroxyl group, a nitro group, a cyano group, a halogen, a carboxyl group, an optionally substituted amino group, a silicon-containing group, a monocyclic aryloxy group, an optionally substituted C1-C6 alkoxy group, an optionally substituted C1-C6 alkylcarbonyl group, an optionally substituted C1-C6 alkyl group, or an optionally substituted C3-C6 cycloalkyl group; alternatively, R1 and R2 are connected via one to three other atoms to form a heterocyclic ring; and in another embodiment, R3 and R4 are oxygen atoms and connected via —O—(CH2)n—O—, forming a ring, in which n=I or 2. The compound has great water-solubility, chemical stability, and great efficacy in treatment on cancer.

Abstract: The present invention relates to a water soluble derivative of camptothecin and preparation method thereof, the derivative having a structure of formula I and being appropriate in water solubility, and having anti-cancer activity and stability of lactonic ring. The present invention also relates to a method for synthesizing the compound and medical use of the compound.

Abstract: The present invention relates to a camptothecin derivative having a structure as represented by Formula (II), in which Xn+ is selected from H+, K+, Na+, Li+, Mg2+, Ca2+, Zn2+, Fe3+, and ammonium ion, while R1, R2, R3, and R4 independently represent a hydrogen, a hydroxyl group, a nitro group, a cyano group, a halogen, a carboxyl group, an optionally substituted amino group, a silicon-containing group, a monocyclic aryloxy group, an optionally substituted C1-C6 alkoxy group, an optionally substituted C1-C6 alkylcarbonyl group, an optionally substituted C1-C6 alkyl group, or an optionally substituted C3-C6 cycloalkyl group; alternatively, R1 and R2 are connected via one to three other atoms to form a heterocyclic ring; and in another embodiment, R3 and R4 are oxygen atoms and connected via —O—(CH2)n—O—, forming a ring, in which n=I or 2. The compound has great water-solubility, chemical stability, and great efficacy in treatment on cancer.

Abstract: The invention provides compounds capable of treating against hepatitis infections, particularly hepatitis B viral infections. Compounds of the invention are nucleic acid-based and preferably comprise 2, 3, 4, 5 or 6 nucleoside units.

Abstract: The invention provides compounds capable of treating against hepatitis infections, particularly hepatitis B viral infections. Compounds of the invention are nucleic acid-based and preferably comprise 2, 3, 4, 5 or 6 nucleoside units.

Abstract: The invention provides compounds capable of treating against hepatitis infections, particularly hepatitis B viral infections. Compounds of the invention are nucleic acid-based and preferably comprise 2, 3, 4, 5 or 6 nucleoside units.

Abstract: The invention provides compounds capable of treating against hepatitis infections, particularly hepatitis B viral infections. Compounds of the invention are nucleic acid-based and preferably comprise 2, 3, 4, 5 or 6 nucleoside units.

Abstract: The invention provides compounds capable of treating against hepatitis infections, particularly hepatitis B viral infections. Compounds of the invention are nucleic acid-based and preferably comprise 2, 3, 4, 5 or 6 nucleoside units.

Abstract: The invention provides new methods for synthesis of nucleotide-based compounds and new libraries of such compounds. Compounds of the invention are useful for a variety of therapeutic applications, including treatment of viral or bacterial infections and associated diseases and disorders.

Abstract: The invention provides new methods for synthesis of nucleotide-based compounds and new libraries of such compounds. Compounds of the invention are useful for a variety of therapeutic applications, including treatment of viral or bacterial infections and associated diseases and disorders.

Abstract: The invention provides compounds capable of treating against hepatitis infections, particularly hepatitis B viral infections. Compounds of the invention are nucleic acid-based and preferably comprise 2, 3, 4, 5 or 6 nucleoside units.

Abstract: The invention provides methods for solution-phase synthesis of nucleotide-based compounds and new libraries of such compounds. Compounds of the invention are useful for a variety of therapeutic applications, including treatment of viral or bacterial infections and associated diseases and disorders.